Translational Research in Pleural Diseases

Pleural Disease: Second Edition

Volumn , Issue , 2009, Pages 182-197

  Stathopoulos, Georgios T ^a   Hegmans, Joost P J J ^b   Lee, Y C Gary ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952255920     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420077391-16     Document Type: Chapter

References (112)

1. Light RW, Lee YCG. Textbook of Pleural Diseases, 2nd ed. London, U.K.: Arnold Press, 2008.
2. Wagenfeld L, Zeitz O, Richard G. Visual loss after povidone-iodine pleurodesis. New Engl J Med 2007; 357: 1264-1265.
3. Davies HE, Lee YC, Davies RJ. Pleurodesis for malignant pleural effusion: talc, toxicity and where next? Thorax 2008; 63: 572-574.
4. West SD, Davies RJO, Lee YCG. Pleurodeses for malignant pleural effusions: Current controversies and variations in practices. Curr Opin Pulm Med 2004; 10: 305-310.
5. West SD, Lee YCG. Current management of malignant pleural mesothelioma. Clin Chest Med 2006; 27: 335-354.
6. Dresler CM, Olak J, Herndon II JE, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909-915.
7. Stathopoulos GT, Lee YCG. Experimental Models: Pleural diseases other thanmesothelioma. In: Light RW, Lee YC (eds.), Textbook of Pleural Diseases (2nd ed.). London, UK: Hodder-Arnold, 2007: 169-186.
8. Lee YCG. Mesothelial cell in pleural disease: An active player or innocent bystander. In: Luh K-T, ed. 7th Congress of the Asian Pacific Society of Respirology. Taipei, Taiwan: Monduzzi Editore-MEDIMOND Inc., 2002: 101-105.
9. Ribera E, Ocaña I, Martinez-Vazquez JM, et al. High level of interferon gamma in tuberculous pleural effusion. Chest 1988; 93: 308-311.
10. Shimokata K, Kishimoto H, Takagi E, et al. Determination of the T-cell subset producing gamma-interferon in tuberculous pleural effusion. Microbiol Immunol 1986; 30: 353-361.
11. Ribera E, Ocaña I, Martinez-Vazquez JM, et al. High level of interferon gamma in tuberculous pleural effusion. Chest 1988; 93: 308-311.
12. Lee YC, Rogers JT, Rodriguez RM, et al. Adenosine deaminase levels in nontuberculous lymphocytic pleural effusions. Chest 2001; 120: 356-361.
13. Mazurek GH, Jereb J, Lobue P, et al. Division of Tuberculosis Elimination, NationalCenter for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using theQuantiFERON-TBGold test for detectingmycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54: 49-55.
14. Hotta K, Ogura T, Nishii K, et al. Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students. PLoS ONE 2007; 2: e803.
15. Villena V, López-Encuentra A, Pozo F, et al. Interferon gamma levels in pleural fluid for the diagnosis of tuberculosis. Am J Med 2003; 115: 365-370.
16. Valdés L, San José E, Alvarez D, et al. Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma. Chest 1993; 103: 458-465.
17. Ocaña I, Martinez-Vazquez JM, Segura RM, et al. Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion. Chest 1983; 84: 51-53.
18. Daniil ZD, Zintzaras E, Kiropoulos T, et al. Discrimination of exudative pleural effusions based on multiple biological parameters. Eur Respir J 2007; 30: 957-964.
19. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999; 85: 178-187.
20. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999; 54: 707-710.
21. Cheng D, Rodriguez RM, Perkett EA, et al. Vascular endothelial growth factor in pleural fluid. Chest 1999; 116: 760-765.
22. Sack U, Hoffmann M, Zhao XJ, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 2005; 25: 600-604.
23. Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000; 6: 957-965.
24. Yano S, Shinohara H, Herbst RS, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. AmJ Pathol 2000; 157: 1893-1903.
25. Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med 2005; 353: 740-741.
26. Pichelmayer O, Gruenberger B, Zielinski C, et al. Bevacizumab is active in malignant effusion. Ann Oncol 2006; 17: 1853.
27. Stathopoulos GT, Moschos C, Loutrari H, et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit CareMed 2008; 178: 50-59 [Epub ahead of print] doi: 10.1164/rccm.200710-1513OC.
28. Lee YCG, Lane KB. Cytokines in pleural diseases. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases. London, U.K.: Arnold Press, 2003: 63-89.
29. Marchi E, Liu W, Broaddus VC. Mesothelial cell apoptosis is confirmed in vivo by morphological change in cytokeratin distribution. Am J Physiol Lung Cell Mol Physiol 2000; 278: L528-L535.
30. Antony VB, Owen CL, Hadley KJ. Pleural mesothelial cells stimulated by asbestos release chemotactic activity for neutrophils in vitro. Am Rev Respir Dis 1989; 139(1): 199-206.
31. Lee YCG, Knight DA, Lane KB, et al. Activation of proteinase activated receptor-2 in mesothelial cells induces pleural inflammation. Am J Physiol Lung Cell Mol Physiol 2005; 288: L734-L740.
32. Lee YCG, Malkerneker D, Thompson PJ, et al. Transforming growth factor-β induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit Care Med 2002; 165: 88-94.
33. Marchi E, Vargas FS, Acencio MMP, et al. Pleurodesis: A novel experimental model. Respirology 2007; 12: 500-504.
34. Light RW, Cheng DS, Lee YCG, et al. A single intrapleural injection of transforming growth factor beta-2 produces an excellent pleurodesis in rabbits. Am J Respir Crit Care Med 2000; 162: 98-104.
35. Lee YCG, Lane KB, Parker RE, et al. Transforming growth factor beta-2 (TGFb2) produces effective pleurodesis in sheep with no systemic complications. Thorax 2000; 55: 1058-1062.
36. Werebe EC, Pazetti R, Milanez de Campos JR, et al. Systemic distribution of talc after intrapleural administration in rats. Chest 1999; 115: 190-193.
37. Cohen RG, Shely WW, Thompson SE, et al. Talc pleurodesis: Talc slurry versus thoracoscopic talc insufflation in porcine model. Ann Thorac Surg 1996; 62: 1000-1002.
38. Ferrer J, Montes JF, Villarino MA, et al. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002; 122: 1018-1027.
39. Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170: 377-382.
40. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: A prospective cohort study. Lancet 2007; 369: 1535-1539.
41. Yeh HH, Lai WW, Chen HH, et al. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006; 25: 4300-4309.
42. Stathopoulos GT, Zhu Z, Everhart MB, et al. Nuclear factor-kappaBaffects tumor progression in amousemodel ofmalignant pleural effusion. Am J RespirCell Mol Biol 2006; 34: 142-150.
43. Stathopoulos GT, Kollintza A, Moschos C, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 2007; 67: 9825-9834.
44. Kraus-Berthier L, Jan M, Guilbaud N, et al. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 2000; 6: 297-304.
45. Astoul P, Colt HG, Wang X, et al. Metastatic human pleura ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice. Anticancer Res 1993; 13: 1999-2002.
46. Kimura K, Nishimura H, Matsuzaki T, et al. Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model. Cancer Immunol Immunother 2000; 49: 71-77.
47. Kraus-Berthier L, Jan M, Guilbaud N, et al. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 2000; 6: 297-304.
48. Wang B, Xiong Q, Shi Q, et al. Genetic disruption of host nitric oxide synthase II gene impairs melanoma-induced angiogenesis and suppresses pleural effusion. Int J Cancer 2001; 91: 607-611.
49. Bliven ML, Otterness IG. Carrageenan pleurisy. Methods Enzymol 1988; 162: 334-339.
50. Vinegar R, Truax JF, Selph JL, et al. Pathway of onset, development and decay of carrageenan pleurisy in the rat. Fed Proc 1982; 41: 2588-2595.
51. Strange C, Tomlinson JR, Wilson C, et al. The histology of experimental pleural injury with tetracycline, empyema and carrageenan. Exp Mol Pathol 1989; 51: 205-219.
52. Klein A, Talvani A, Cara DC, et al. Stem cell factor plays a major role in the recruitment of eosinophils in allergic pleurisy in mice via the production of leukotriene B4. J Immunol 2000; 164: 4271-4276.
53. Pasquale CP, E-Silva PM, Lima MC, et al. Suppression by cetirizine of pleurisy triggered by antigen in actively sensitized rats. Eur J Pharmacol 1992; 223: 9-14.
54. Martins MA, Castro-Faria-Neto HC, Bozza PT, et al. Role of PAF in the allergic pleurisy caused by ovalbumin in actively sensitized rats. J Leukoc Biol 1993; 53: 104-111.
55. Martins MA, Pasquale CP, E-Silva PM, et al. Eosinophil accumulation in the rat pleural cavity after mast cell stimulation with compound 48/80 involves protein synthesis and is selectively suppressed by dexamethasone. Int Arch Allergy Appl Immunol 1990; 92: 416-424.
56. Mohammed KA, Nasreen N, Ward MJ, et al. Induction of acute pleural inflammation by Staphylococcus aureus. I. CD4+ T cells play a critical role in experimental empyema. J Infect Dis 2000; 181: 1693-1699.
57. Sasse S, Nguyen T, Texeira LR, et al. The utility of daily therapeutic thoracentecis for the treatment of early empyema. Chest 1999; 116: 1703-1708.
58. Sasse S, Nguyen TK, Mulligan M, et al. The effects of early chest tube placement on empyema resolution. Chest 1997; 111: 1679-1683.
59. Zhu Z, Hawthorne ML, Guo Y, et al. Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model. Chest 2006; 129: 1577-1583.
60. Strahilevitz J, Lev A, Levi I, et al. Experimental pneumococcal pleural empyema model: The effect of moxifloxacin. J Antimicrob Chemother 2003; 51: 665-669.
61. Teixeira LR, Sasse SA, Villarino MA, et al. Antibiotic levels in empyemic pleural fluid. Chest 2000; 117: 1734-1739.
62. Liapakis IE, Light RW, Pitiakoudis MS, et al. Penetration of clarithromycin in experimental pleural empyema model fluid. Respiration 2005; 72: 296-300.
63. Sandhu H, Dehnen W, Roller M, et al. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis 2000; 21: 1023-1029.
64. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-1573.
65. Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 1993; 142: 1524-1533.
66. Marzo AL, Fitzpatrick DR, Robinson BWS, et al. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997; 57: 3200-3207.
67. Janne PA, Taffaro ML, Salgia R, et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002; 62: 5242-5247.
68. Mazieres J, You L, He B, et al. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer 2005; 117: 326-332.
69. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998; 16: 3087-3095.
70. Scagliotti GV, Novello S. State of the art in mesothelioma. Ann Oncol 2005; 16: ii240-ii245.
71. Khokhar NZ, She Y, Rusch VW, et al. Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: Further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Clin Cancer Res 2001; 7(10): 3199-3205.
72. Allen SS, McMurray DN. Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs. Infect Immun 2003; 71: 4271-4277.
73. Allen SS, Cassone L, Lasco TM, et al. Effect of neutralizing transforming growth factor β1 on the immune response against mycobacterium tuberculosis in guinea pigs. Infect Immun 2004; 72: 1358-1363.
74. Quachenbush J. Microarray analysis and tumor classification. New Engl J Med 2006; 354: 2463-2472.
75. Hegmans J, Lambrecht B. Proteomics in pleural disease. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases, 2nd ed. London, U.K.: Arnold Press, 2008.
76. Sugarbaker DJ, Richards WG, Gordon GJ, et al. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A 2008; 105(9): 3521-3526.
77. Lindholm PM, Salmenkivi K, Vauhkonen H, et al. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 2007; 119(1-2): 46-52.
78. Pusztai L. Chips to bedside: Incorporation of microarray data into clinical practice. Clin Cancer Res 2006; 12: 7209-7214.
79. Wiltgen M, Tilz GP. DNA microarray analysis: Principles and clinical impact. Hematology 2007; 12: 271-287.
80. Zanazzi C, Hersmus R, Veltman IM, et al. Gene expression profiling and gene copynumber changes in malignant mesothelioma cell lines. Genes Chromosomes Cancer 2007; 46(10): 895-908.
81. Mohr S, Bottin MC, Lannes B, et al. Microdissection, mRNA amplification and microarray: A study of pleural mesothelial and malignant mesothelioma cells. Biochimie 2004; 86(1): 13-19.
82. Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005; 166: 1827-1840.
83. Hoang CD, D’Cunha J, Kratzke MG, et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004; 125: 1843-1852.
84. Singhal S, Wiewrodt R, Malden LD, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003; 9: 3080-3097.
85. Ramos-Nino ME, Scapoli L, Martinelli M, et al. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 2003; 63: 3539-3545.
86. Kettunen E, Nissen AM, Ollikainen T, et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer 2001; 91(4): 492-496.
87. Holloway AJ, Diyagama DS, Opeskin K, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res 2006; 12: 5129-5135.
88. Davidson B, Espina V, Steinberg SM, et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 2006; 12: 791-799.
89. Sun X, Wei L, Liden J, et al. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol 2005; 207(1): 91-101.
90. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002; 62: 4963-4967.
91. Gordon GJ, Rockwell GN, Godfrey PA, et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005; 11: 4406-4414.
92. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003; 95: 598-605.
93. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004; 10: 849-859.
94. Fields S. Proteomics in genomeland. Science 2001; 291: 1221-1224.
95. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004; 4: 3665-3685.
96. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422: 198-207.
97. Davidson B, Espina V, Steinberg SM, et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 2006; 12: 791-799.
98. Hsieh WY, Chen MW, Ho HT, et al. Identification of differentially expressed proteins in human malignant pleural effusions. Eur Respir J 2006; 28: 1178-1185.
99. Tyan YC, Wu HY, Su WC, et al. Proteomic analysis of human pleural effusion. Proteomics 2005; 5: 1062-1074.
100. Tyan YC, Wu HY, Lai WW, et al. Proteomic profiling of human pleural effusion using twodimensional nano liquid chromatography tandem mass spectrometry. J Proteome Res 2005; 4: 1274-1286.
101. Adkins JN, Varnum SM, Auberry KJ, et al. Toward a human blood serum proteome: Analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1: 947-955.
102. Fetsch PA, Simone NL, Bryant-Greenwood PK, et al. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: Potential for diagnostic applications. Am J Clin Pathol 2002; 118: 870-876.
103. Soltermann A, Ossola R, Kilgus-Hawelski S, et al. N-Glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer 2008; 114: 124-133.
104. Yanagisawa Y, Sato Y, Asahi-Ozaki Y, et al. Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma. J Pathol 2006; 209: 464-473.
105. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003; 362: 433-439.
106. Davidson B. Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. Curr Cancer Drug Targets 2007; 7: 109-120.
107. Bard MP, Hegmans JP, Hemmes A, et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 2004; 31: 114-121.
108. Thery C, Boussac M, Veron P, et al. Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001; 166: 7309-7318.
109. Hegmans JP, Bard MP, Hemmes A, et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol 2004; 164: 1807-1815.
110. Kothmaier H, Quehenberger F, Halbwedl I, et al. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 2008; 63: 345-351.
111. Hegmans JP, Hemmes A, Hammad H, et al. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006; 27: 1086-1095.
112. Mischak H, Apweiler R, Banks RE, et al. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007; 1: 148-156.